Mondego Bio is a new Portuguese startup developing breakthrough cancer treatments. Mondego Bio was founded by these three investors and represents Biovance Capital Fund I's inaugural investment. LISBON, Portugal, Sept. 18, 2025 /PRNewswire/ -- Biovance Capital Partners, a biotech venture capital firm based in Lisbon, Portugal, alongside co-investors OrbiMed, a leading healthcare investment firm, with over $17 billion in assets under management and Torrey Pines Investment, a specialty life-scie

Eli Lilly's dual GIP/GLP-1 agonist Mounjaro (tirzepatide) met all primary and key secondary endpoints in a late-stage paediatric study, demonstrating significant HbA1c and BMI reductions in children and adolescents with inadequately controlled type 2 diabetes (T2D). The detailed findings were presented at the European Association for the Study of Diabetes (EASD) meeting on Wednesday and concurrently published in The Lancet.Highlighting the rapidly growing incidence of T2D and an unmet treatment

Roche agreed to acquire 89bio for $14.50 per share in cash, or around $2.4 billion, adding the late-stage FGF21 analogue pegozafermin to its cardiovascular, renal, and metabolic disease portfolio. The deal announced Thursday also includes a contingent value right (CVR) worth up to $6 per share in cash, giving the transaction a total potential value of $3.5 billion. Pegozafermin is currently being studied in the Phase III ENLIGHTEN programme, which is investigating the once-weekly therapy in pati

SAN FRANCISCO and SUZHOU, China, Sept. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin reported a clinical update on IBI324 (Ollin R&D code: OLN324). IBI324 (OLN324) is a higher potency, highe

Meaningful improvements confirmed in slow-progressor subgroup; biomarker reductions support precision-medicine approach and potential FDA accelerated pathway SEOUL, South Korea, Sept. 17, 2025 /PRNewswire/ -- CorestemChemon Inc. (KOSDAQ: 166480) announced today that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® (lenzumestrocel), an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), at the PACTALS 2025 congre

YANTAI, China, Sept. 17, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusion protein innovative drug independently developed by RemeGen) for the treatment of generalized myasthenia gravis (gMG) was selected as an oral presentation at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. T

SHANGHAI, Sept. 17, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the updated long-term follow-up results of Phase I clinical trial of zevorcabtagene autoleucel (zevor-cel, R&D code: CT053, an autologous CAR T-cell product targeting BCMA) have been presented as a poster at the 22nd International Myeloma Society ("IMS") Annual Meeting. The poster was titled "Long term Follow-up of Z

CAMBRIDGE, UK and MONTREAL, CANADA, 18 September 2025 – Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the appointment of four world leading experts to its Scientific Advisory Board (SAB): Prof. Nahum Sonenberg, Dr. Nina Bhardwaj, Dr. Maggie Callahan, and Dr. Craig L. Slingluff, Jr. Together, they bring deep expertise in immuno-oncology, translational research, and vaccine development, supporting Epitope

--Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne compared with placebo. --Denifanstat (ASC40) demonstrated a favorable safety and tolerability profile. Treatment emergent adverse events (TEAEs) in the denifanstat (ASC40) group were comparable to placebo: 58.6% versus 56.3%. The majority of TEAEs were mild (Grade 1) or moderate (Grade 2). --Pre-New Drug Application (NDA) consultation of denifans

PARIS, Sept. 18, 2025 /PRNewswire/ -- Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major cardiovascular events compared to those taking other diabetes or weight-loss medications, new research has shown. The study – the largest of its kind and presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2025 – also found that GLP-1RAs significantly reduced the risk of alcohol